Filing Analysis
📢 Regulation FD Disclosure
Filed May 13, 2026
⚪ LOW
Journey Medical Corporation announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The information was furnished via a press release attached as Exhibit 99.1.
📋 Key Facts
- The report covers the three-month period ended March 31, 2026.
- The filing was made on May 13, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The press release (Exhibit 99.1) includes both financial results and a general corporate update.
📄 Other SEC Filing
Filed Apr 21, 2026
⚪ LOW
Journey Medical Corporation announced an expansion in pharmacy benefit coverage for Emrosi™, its treatment for inflammatory lesions of rosacea in adults. The announcement was made via a press release on April 21, 2026, and filed under Item 8.01.
📋 Key Facts
- The product involved is Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules).
- The expansion pertains to pharmacy benefit coverage, which typically improves patient access and potential sales volume.
- The announcement was dated April 21, 2026.
- The filing includes a press release as Exhibit 99.1.
📢 Regulation FD Disclosure
Filed Mar 25, 2026
⚪ LOW
Journey Medical Corporation announced its financial results for the full year ended December 31, 2025, and provided a corporate update via a press release on March 25, 2026.
📋 Key Facts
- The company reported financial results for the fiscal year ended December 31, 2025.
- The announcement was made on March 25, 2026.
- The press release was furnished under Item 2.02 and included as Exhibit 99.1.
- Journey Medical is classified as an emerging growth company.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.